Sphera Funds Management’s Skye Bioscience SKYE Stock Holding History

Sphera Funds Management’s Portfolio SKYE Stock Details SKYE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Hold	84,866	–	–	0.06%	101
2026 Q1	$417K	Buy	84,866 +25,000	+42%	+$163K	0.07%	93
2025 Q4	$359K	Hold	59,866	–	–	0.07%	93
2025 Q3	$1.88M	Sell	59,866 -7,438	-11%	-$225K	0.4%	74
2025 Q2	$2.25M	Sell	67,304 -117,240	-64%	-$1.94M	0.53%	62
2025 Q1	$2.35M	Sell	184,544 -11,035	-6%	-$241K	0.54%	57
2024 Q4	$4.43M	Buy	195,579 +139	+0.1%	+$4.65K	0.8%	45
2024 Q3	$6.11M	Buy	195,440 +33,151	+20%	+$1.49M	0.97%	37
2024 Q2	$10.4M	Buy	+162,289	New	+$15.4M	1.42%	23

Other funds holding SKYE

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's SKYE Position: Q2 2026 in Review

Sphera Funds Management held its Skye Bioscience (SKYE) position steady in Q2 2026 at 84,866 shares worth $471K. The position accounts for 0.06% of the portfolio, ranked #101.

Sphera Funds Management first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $10.4M in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

Sphera Funds Management held 84,866 shares of Skye Bioscience worth $471K as of Q2 2026.
Sphera Funds Management left its Skye Bioscience share count unchanged in Q2 2026.
Skye Bioscience made up 0.06% of Sphera Funds Management's portfolio in Q2 2026, its #101 holding.
Sphera Funds Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
Sphera Funds Management's Skye Bioscience position peaked at $10.4M in Q2 2024.
33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.